Diagnosis and clinical management of red cell membrane disorders.
Kalfa, TA.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program.
2021;
2021:331-340.
Characterizing bulk rigidity of rigid red blood cell populations in sickle-cell disease patients.
Gutierrez, M; Shamoun, M; Seu, KG; Tanski, T; Kalfa, TA; Eniola-Adefeso, O.
Scientific Reports.
2021;
11.
SERF1 Is Required for G-CSF Resistance of Start-Codon Mutant ELANE Granulocytic Precursors.
Nayak, RC; Trump, L; Emberesh, S; Lee, Y; Singh, AK; Wellendorf, AM; Horwitz, MS; Kalfa, TA; Lutzko, C; Cancelas, JA.
Blood.
2021;
138:433-433.
Overexpression of Human TLR8 Causes Fatal Anemia in SLE-Prone Mice By Altering the Bone Marrow Erythropoietic Niche.
Davidson, A; Maria, N; Papoin, J; Raparia, C; Sun, Z; Zhang, W; Kalfa, TA; Paulson, R; Blanc, L.
Blood.
2021;
138:1989-1989.
Activation of Pyruvate Kinase-R with Etavopivat (FT-4202) Is Well Tolerated, Improves Anemia, and Decreases Intravascular Hemolysis in Patients with Sickle Cell Disease Treated for up to 12 Weeks.
Brown, RC C; Saraf, SL; Cruz, K; Idowu, M; Kalfa, TA; Geib, J; Forsyth, S; Schroeder, P; Wu, E; Kelly, P; et al.
Blood.
2021;
138:9-9.
Etavopivat, an Allosteric Activator of Pyruvate Kinase-R, Improves Sickle RBC Functional Health and Survival and Reduces Systemic Markers of Inflammation and Hypercoagulability in Patients with Sickle Cell Disease: An Analysis of Exploratory Studies in a Phase 1 Study.
Kalfa, TA; Telen, MJ; Saraf, SL; Brown, RC C; Giger Seu, K; Larkin, SK; Ribadeneira, MD; Schroeder, P; Wu, E; Kelly, P; et al.
Blood.
2021;
138:8-8.
Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease.
Lal, A; Brown, RC C; Coates, TD; Kalfa, TA; Kwiatkowski, JL; Brevard, J; Potter, V; Wood, KW; Sheth, S.
Blood.
2021;
138:4162-4162.